Anna Norhammar

List of Publications by Year
in descending order

106 papers	10,265 citations	81743 39 h-index	34900 98 g-index
107 all docs	107 docs citations	107 times ranked	9629 citing authors

#	Article	IF	Citations
1	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 2020, 41, 255-323.	1.0	2,811
2	Glycometabolic State at Admission: Important Risk Marker of Mortality in Conventionally Treated Patients With Diabetes Mellitus and Acute Myocardial Infarction. Circulation, 1999, 99, 2626-2632.	1.6	1,181
3	Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet, The, 2002, 359, 2140-2144.	6.3	968
4	Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs. Circulation, 2017, 136, 249-259.	1.6	672
5	Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs. Journal of the American College of Cardiology, 2018, 71, 2628-2639.	1.2	370
6	Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes and Endocrinology,the, 2017, 5, 709-717.	5.5	285
7	Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. Journal of the American College of Cardiology, 2004, 43, 585-591.	1.2	267
8	Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. European Heart Journal, 2004, 25, 1990-1997.	1.0	225
9	Periodontitis Increases the Risk of a First Myocardial Infarction. Circulation, 2016, 133, 576-583.	1.6	200
10	Dapagliflozin is associated with lower risk of cardiovascular events and allâ€cause mortality in people with type 2 diabetes (<scp>CVDâ€REAL Nordic</scp>) when compared with dipeptidyl peptidaseâ€4 inhibitor therapy: <scp>A</scp> multinational observational study. Diabetes, Obesity and Metabolism, 2018, 20, 344-351.	2.2	164
11	The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. European Heart Journal, 2007, 29, 166-176.	1.0	149
12	Improved but still high short- and long-term mortality rates after myocardial infarction in patients with diabetes mellitus: a time-trend report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission. Heart, 2006, 93, 1577-1583.	1.2	131
13	Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study. Diabetes, Obesity and Metabolism, 2020, 22, 1607-1618.	2.2	118
14	SGLT-2 Inhibitors and Cardiovascular Risk. Journal of the American College of Cardiology, 2018, 71, 2497-2506.	1.2	113
15	Diabetes, Insulin Resistance, and the Metabolic Syndrome in Patients With Acute Myocardial Infarction Without Previously Known Diabetes. Diabetes Care, 2003, 26, 2770-2776.	4.3	112
16	Under utilisation of evidence-based treatment partial explanation for the unfavourable prognosis in diabetic patients with acute myocardial infarction. European Heart Journal, 2003, 24, 838-844.	1.0	111
17	Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulinâ€“Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study. Diabetologia, 2011, 54, 1308-1317.	2.9	94
18	Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006â€“2013. Diabetologia, 2016, 59, 1692-1701.	2.9	93

#	Article	IF	Citations
19	Type 2 diabetes and cardiovascular disease in women. Diabetologia, 2013, 56, 1-9.	2.9	92
20	Abnormal glucose tolerance - a common risk factor in patients with acute myocardial infarction in comparison with population-based controls. Journal of Internal Medicine, 2004, 256, 288-297.	2.7	86
21	Oral Glucose Tolerance Test: A Reliable Tool for Early Detection of Glucose Abnormalities in Patients With Acute Myocardial Infarction in Clinical Practice: A report on repeated oral glucose tolerance tests from the GAMI Study. Diabetes Care, 2008, 31, 36-38.	4.3	86
22	Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (<scp>US</scp>, <scp>UK</scp> and Sweden). European Journal of Heart Failure, 2021, 23, 1499-1511.	2.9	80
23	Prognostic Implications of TypeÂ2ÂDiabetesÂMellitus in IschemicÂandÂNonischemic Heart Failure. Journal of the American College of Cardiology, 2016, 68, 1404-1416.	1.2	77
24	Novel oral glucoseâ€lowering drugs are associated with lower risk of allâ€cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 831-841.	2.2	75
25	Intensified insulin-based glycaemic control after myocardial infarction: mortality during 20 year follow-up of the randomised Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI 1) trial. Lancet Diabetes and Endocrinology,the, 2014, 2, 627-633.	5.5	73
26	Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality. Diabetes Research and Clinical Practice, 2016, 117, 39-47.	1.1	68
27	Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study. Lancet Diabetes and Endocrinology,the, 2020, 8, 606-615.	5.5	67
28	How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study. Diabetes, Obesity and Metabolism, 2019, 21, 968-974.	2.2	66
29	Rates of myocardial infarction and stroke in patients initiating treatment with <scp>SGLT</scp>2â€inhibitors versus other glucoseâ€lowering agents in realâ€world clinical practice: <scp>R</scp>esults from the <scp>CVDâ€REAL</scp> study. Diabetes, Obesity and Metabolism, 2018, 20, 1983-1987.	2.2	65
30	Beta cell dysfunction in patients with acute myocardial infarction but without previously known type 2 diabetes: a report from the GAMI study. Diabetologia, 2005, 48, 2229-2235.	2.9	62
31	Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLAREâ€TIMI 58 trial: A nationwide observational study. Diabetes, Obesity and Metabolism, 2019, 21, 1136-1145.	2.2	61
32	High Event Rate After a First Percutaneous Coronary Intervention in Patients With Diabetes Mellitus. Circulation: Cardiovascular Interventions, 2015, 8, e002328.	1.4	54
33	Hyperglycaemia and cardiovascular disease. Journal of Internal Medicine, 2007, 262, 145-156.	2.7	52
34	IGF Binding Protein 1 Predicts Cardiovascular Morbidity and Mortality in Patients With Acute Myocardial Infarction and Type 2 Diabetes. Diabetes Care, 2007, 30, 2343-2348.	4.3	51
35	Sustained prognostic implications of newly detected glucose abnormalities in patients with acute myocardial infarction: Long-term follow-up of the Glucose Tolerance in Patients with Acute Myocardial Infarction cohort. Diabetes and Vascular Disease Research, 2015, 12, 23-32.	0.9	49
36	Effects of improved metabolic control on platelet reactivity in patients with type 2 diabetes mellitus following coronary angioplasty. Diabetes and Vascular Disease Research, 2006, 3, 52-56.	0.9	48

#	Article	IF	Citations
37	Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia. Diabetes Research and Clinical Practice, 2017, 123, 199-208.	1.1	44
38	Salivary Matrix Metalloproteinase-8 and -9 and Myeloperoxidase in Relation to Coronary Heart and Periodontal Diseases: A Subgroup Report from the PAROKRANK Study (Periodontitis and Its Relation to) Tj ETQq0 0 1 rgBT /Overlock 10	1.1	44
39	Lower cardiorenal risk with <scp>sodiumâ€glucose</scp> cotransporterâ€2 inhibitors versus dipeptidyl peptidaseâ€4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study. Diabetes, Obesity and Metabolism, 2021, 23, 75-85.	2.2	43
40	Is the prognosis in patients with diabetes and heart failure a matter of unsatisfactory management? An observational study from the Swedish Heart Failure Registry. European Journal of Heart Failure, 2014, 16, 409-418.	2.9	42
41	Diabetes: Prevalence, prognosis and management of a potent cardiovascular risk factor. European Journal of Preventive Cardiology, 2017, 24, 52-60.	0.8	41
42	Type 2 diabetes and heart failure: Characteristics and prognosis in preserved, mid-range and reduced ventricular function. Diabetes and Vascular Disease Research, 2018, 15, 494-503.	0.9	37
43	Risk factors, treatment and prognosis in men and women with heart failure with and without diabetes. Heart, 2015, 101, 1139-1148.	1.2	36
44	Cardiovascular and Renal Disease Burden in Type 1 Compared With Type 2 Diabetes: A Two-Country Nationwide Observational Study. Diabetes Care, 2021, 44, 1211-1218.	4.3	32
45	Long-term mortality after PCI in patients with diabetes mellitus: results from the Swedish Coronary Angiography and Angioplasty Registry. EuroIntervention, 2010, 5, 891-897.	1.4	26
46	Insulin-like growth factor I: a predictor of long-term glucose abnormalities in patients with acute myocardial infarction. Diabetologia, 2006, 49, 2247-2255.	2.9	25
47	High overall cardiovascular risk and mortality in patients with atrial fibrillation and diabetes: A nationwide report. Diabetes and Vascular Disease Research, 2018, 15, 31-38.	0.9	25
48	Different patterns of secondâ€line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study. Endocrinology, Diabetes and Metabolism, 2018, 1, e00036.	1.0	24
49	Heart failure is a common complication after acute myocardial infarction in patients with diabetes: A nationwide study in the SWEDEHEART registry. European Journal of Preventive Cardiology, 2020, 27, 1890-1901.	0.8	24
50	Glucagon-like peptide-1 receptor agonists and the risk of cardiovascular events in diabetes patients surviving an acute myocardial infarction. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 104-111.	1.4	23
51	Long-term mortality in patients with type 2 diabetes undergoing coronary angiography: the impact of glucose-lowering treatment. Diabetologia, 2012, 55, 2109-2117.	2.9	22
52	Glycaemic control and restenosis after percutaneous coronary interventions in patients with diabetes mellitus: a report from the Insulin Diabetes Angioplasty study. Diabetes and Vascular Disease Research, 2009, 6, 71-79.	0.9	20
53	Implications of abnormal glucose metabolism in patients with coronary artery disease. Diabetes and Vascular Disease Research, 2008, 5, 285-290.	0.9	19
54	Copeptin in patients with acute myocardial infarction and newly detected glucose abnormalities â€“ A marker of increased stress susceptibility? A report from the Glucose in Acute Myocardial Infarction cohort. Diabetes and Vascular Disease Research, 2017, 14, 69-76.	0.9	19

#	Article	IF	Citations
55	Elevated levels of adipokines predict outcome after acute myocardial infarction: A long-term follow-up of the Glucose Tolerance in Patients with Acute Myocardial Infarction cohort. Diabetes and Vascular Disease Research, 2017, 14, 77-87.	0.9	19
56	Severe Periodontitis Is Associated with Myocardial Infarction in Females. Journal of Dental Research, 2018, 97, 1114-1121.	2.5	19
57	Periodontal disease â€“ important to consider in cardiovascular disease prevention. Expert Review of Cardiovascular Therapy, 2016, 14, 987-989.	0.6	18
58	Impaired fasting glucose: a risk factor for atrial fibrillation and heart failure. Cardiovascular Diabetology, 2021, 20, 227.	2.7	18
59	Symptoms of depression and their relation to myocardial infarction and periodontitis. European Journal of Cardiovascular Nursing, 2017, 16, 468-474.	0.4	17
60	Antiphospholipid Antibodies in Patients With Myocardial Infarction. Annals of Internal Medicine, 2019, 170, 277.	2.0	17
61	Gender differences in screening for glucose perturbations, cardiovascular risk factor management and prognosis in patients with dysglycaemia and coronary artery disease: results from the ESC-EORP EUROASPIRE surveys. Cardiovascular Diabetology, 2021, 20, 38.	2.7	17
62	Prognosis in Patients With Diabetes Mellitus and STEMI Undergoing Primary PCI. Journal of the American College of Cardiology, 2018, 72, 1427-1428.	1.2	16
63	Undetected Dysglycemia Is an Important Risk Factor for Two Common Diseases, Myocardial Infarction and Periodontitis: A Report From the PAROKRANK Study. Diabetes Care, 2019, 42, 1504-1511.	4.3	16
64	Elevated admission glucose is common and associated with high short-term complication burden after acute myocardial infarction: Insights from the VALIDATE-SWEDEHEART study. Diabetes and Vascular Disease Research, 2019, 16, 582-584.	0.9	15
65	The SWEDEHEART secondary prevention and cardiac rehabilitation registry (SWEDEHEART CR registry). European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 431-437.	1.8	15
66	Cardiovascular outcomes with sodiumâ€“glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data. Cardiovascular Diabetology, 2021, 20, 159.	2.7	15
67	Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries. Diabetes, Obesity and Metabolism, 2022, 24, 1277-1287.	2.2	15
68	Diabetes and cardiovascular mortality: the impact of sex. Lancet Diabetes and Endocrinology,the, 2018, 6, 517-519.	5.5	14
69	Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006â€“2014. PharmacoEconomics - Open, 2018, 2, 393-402.	0.9	14
70	The DPP-4 inhibitor sitagliptin and endothelial function in patients with acute coronary syndromes and newly detected glucose perturbations: A report from the BEGAMI study. Diabetes and Vascular Disease Research, 2014, 11, 290-293.	0.9	13
71	Invasive Dental Treatment and Risk for a First Myocardial Infarction. Journal of Dental Research, 2018, 97, 1100-1105.	2.5	12
72	Is Coronary Artery Disease Inevitable in Type 2 Diabetes? From a Glucocentric to a Holistic View on Patient Management. Diabetes Care, 2020, 43, 2001-2009.	4.3	12

#	Article	IF	Citations
73	Association of sodiumâ€glucose cotransporterâ€2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: Analysis from the <scp>CVDâ€REAL</scp> 2 study. Diabetes, Obesity and Metabolism, 2021, 23, 1431-1435.	2.2	12
74	Endodontic inflammatory disease: A risk indicator for a first myocardial infarction. International Endodontic Journal, 2022, 55, 6-17.	2.3	12
75	Saliva and plasma levels of cardiacâ€related biomarkers in postâ€myocardial infarction patients. Journal of Clinical Periodontology, 2017, 44, 692-699.	2.3	10
76	Dapagliflozin vs nonâ€SGLTâ€2i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLAREâ€TIMI 58 trial: A nationwide observational study. Diabetes, Obesity and Metabolism, 2019, 21, 2651-2659.	2.2	10
77	Diabetes, metformin and glucose lowering therapies after myocardial infarction: Insights from the SWEDEHEART registry. Diabetes and Vascular Disease Research, 2020, 17, 147916412097367.	0.9	9
78	Mortality and extent of coronary artery disease in 2776 patients with type 1 diabetes undergoing coronary angiography: A nationwide study. European Journal of Preventive Cardiology, 2017, 24, 848-857.	0.8	8
79	Characteristics and Prognosis in Women and Men With Type 1 Diabetes Undergoing Coronary Angiography: A Nationwide Registry Report. Diabetes Care, 2018, 41, 876-883.	4.3	8
80	Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6â€“10. Diabetes Care, 2018, 41, e106-e108.	4.3	8
81	Long-term prognosis in patients with acute myocardial infarction and newly detected glucose abnormalities: predictive value of oral glucose tolerance test and HbA1c. Cardiovascular Diabetology, 2021, 20, 122.	2.7	7
82	Copeptin, insulin-like growth factor binding protein-1 and sitagliptin: A report from the BEta-cell function in Glucose abnormalities and Acute Myocardial Infarction study. Diabetes and Vascular Disease Research, 2016, 13, 307-311.	0.9	6
83	Response by Kosiborod et al to Letters Regarding Article, â€œLower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of) Tj ETQq1 1 0.784314 rgBT /Ov	1.6	6
84	Elevated levels of insulin-like growth factor-binding protein 1 predict outcome after acute myocardial infarction: A long-term follow-up of the glucose tolerance in patients with acute myocardial infarction (GAMI) cohort. Diabetes and Vascular Disease Research, 2018, 15, 387-395.	0.9	6
85	Copeptin and insulin-like growth factor binding protein-1 during follow-up after an acute myocardial infarction in patients with type 2 diabetes: A report from the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction 2 cohort. Diabetes and Vascular Disease Research, 2019, 16, 22-27.	0.9	6
86	Risk of stent failure in patients with diabetes treated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors: A nationwide observational study. International Journal of Cardiology, 2021, 330, 23-29.	0.8	6
87	Admission Glucose Levels and Associated Risk for Heart Failure After Myocardial Infarction in Patients Without Diabetes. Journal of the American Heart Association, 2021, 10, e022667.	1.6	6
88	Prognostic impact of type 1 and type 2 diabetes mellitus in atrial fibrillation and the effect of severe hypoglycaemia: a nationwide cohort study. European Journal of Preventive Cardiology, 2022, 29, 1759-1769.	0.8	6
89	Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6â€“10. Diabetes Care, 2018, 41, e104-e105.	4.3	5
90	Periodontitis, assessed using periodontal treatment as a surrogate marker, has no association with a first myocardial infarction in a Swedish population. Journal of Periodontology, 2021, 92, 1730-1737.	1.7	4

#	Article	IF	Citations
91	Diabetes and heart failure notions from epidemiology including patterns in low-, middle- and high-income countries. Diabetes Research and Clinical Practice, 2021, 177, 108822.	1.1	4
92	Association of peptidoglycan recognition protein 1 to postâ€myocardial infarction and periodontal inflammation: A subgroup report from the PAROKRANK (Periodontal Disease and the Relation to) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6	1.1	4
93	Measures of Insulin Resistance as a Screening Tool for Dysglycemia in Patients With Coronary Artery Disease: A Report From the EUROASPIRE V Population. Diabetes Care, 2022, 45, 2111-2117.	4.3	4
94	Improved glycemic control due to sitagliptin is not related to cortisol or the surrogate marker IGFBP-1 for hepatic insulin sensitivity. Growth Hormone and IGF Research, 2015, 25, 298-303.	0.5	3
95	Hospitalization for Heart Failure and Death in New Users of SGLT-2 Inhibitors in Patients With and Without Cardiovascular Diseaseâ€"CVD Real Study. Canadian Journal of Diabetes, 2017, 41, S51-S52.	0.4	3
96	Effects of lipid-lowering treatment intensity and adherence on cardiovascular outcomes in patients with a recent myocardial infarction: a Swedish register-based study. Upsala Journal of Medical Sciences, 0, 127, .	0.4	3
97	Association of high cardiovascular risk and diabetes with calcified carotid artery atheromas depicted on panoramic radiographs. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2022, 133, 88-99.	0.2	2
98	Dapagliflozin Is Associated With Lower Risk Of Hospitalization For Kidney Disease, Heart Failure And All Cause Death Compared To DPP-4i: CVD-REAL Nordic. Canadian Journal of Diabetes, 2017, 41, S51.	0.4	1
99	Dapagliflozin is Associated With Lower Risk of Hospitalization for Heart Failure, Major Adverse Cardiovascular Events and All-Cause Death Compared to DPP-4i in T2D Patients: CVD-REAL Nordic. Canadian Journal of Diabetes, 2017, 41, S51.	0.4	1
100	Antiphospholipid antibodies in patients with dysglycaemia: A neglected cardiovascular risk factor?. Diabetes and Vascular Disease Research, 2020, 17, 147916412092212.	0.9	1
101	OR11-4 INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-1 PREDICTS CARDIOVASCULAR EVENTS IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION AND TYPE 2 DIABETES. A REPORT FROM THE DIGAMI 2 TRIAL. Growth Hormone and IGF Research, 2006, 16, S22.	0.5	0
102	Cardiovascular prevention in high-risk patients with type 2 diabetes mellitus: when to start it?: reply. European Heart Journal, 2008, 29, 2058-2059.	1.0	0
103	Problems, Pitfalls and Encouraging Information on Patients with Diabetes and Heart Failure. Cardiology, 2016, 134, 411-412.	0.6	0
104	Response to Comment on Norhammar et al. Undetected Dysglycemia Is an Important Risk Factor for Two Common Diseases, Myocardial Infarction and Periodontitis: A Report From the PAROKRANK Study. Diabetes Care 2019;42:1504â€"1511. Diabetes Care, 2020, 43, e9-e9.	4.3	0
105	Androgen receptor polymorphism, testosterone levels, and prognosis in patients with acute myocardial infarction. European Heart Journal Open, 2021, 1, .	0.9	0
106	Mannose-binding lectin does not explain the dismal prognosis after an acute coronary event in dysglycaemic patients. A report from the GAMI cohort. Cardiovascular Diabetology, 2022, 21, .	2.7	0